Pretransplantation C-Peptide Level Predicts Early Posttransplantation Diabetes Mellitus and Has an Impact on Survival after Allogeneic Stem Cell Transplantation

被引：16

作者：

Griffith, Michelle L. ^{[3
]}

Jagasia, Madan H. ^{[1
]}

Misfeldt, Amanda A. ^{[3
]}

Chen, Heidi ^{[2
]}

Engelhardt, Brian G.

Kassim, Adetola

Savani, Bipin N.

Survant, Margaret ^{[3
]}

Jagasia, Shubhada M. ^{[3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Div Hematol Oncol,Dept Med,Sch Med, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA

[3] Vanderbilt Univ, Sch Med, Div Endocrinol Diabet & Metab, Nashville, TN 37232 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 01期

关键词：

Metabolic complications; BONE-MARROW-TRANSPLANTATION; NEW-ONSET; T-CELLS; CARDIOVASCULAR EVENTS; METABOLIC SYNDROME; GLUCOSE; HYPERTENSION; MULTICENTER; PREVALENCE; RECIPIENTS;

D O I：

10.1016/j.bbmt.2010.06.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Posttransplantation diabetes mellitus (PTDM) is a frequent complication after allogeneic stem cell transplantation (allo-SCT), important for its negative impact on cardiovascular health. Risk factors for PTDM are not well defined. We conducted a prospective study to investigate the risk factors and incidence for PTDM in the first 100 days after allo-SCT. A total of 84 patients completed the study, 60% of whom developed PTDM. In a multivariate logistic regression model, pretransplantation c-peptide level (>3.6 ng/mL; odds ratio [OR], 5.9; 95% confidence interval [Cl], 1.77-20.22; P = .004), unrelated donor allo-SCT (OR, 4.3; 95% Cl, 1.34-14.2; P = .014), and peak steroid dose >1 mg/kg/day (OR, 5.09; 95% Cl, 1.19-23.2; P = .035) were identified as independent predictors of PTDM. In addition, overall survival (OS) was inferior in patients with PTDM compared with those without PTDM (mean survival, 2.26 years vs 2.7 years; P = .021). Pretransplantation c-peptide level greater than the cohort median (>3.6 ng/mL) also was associated with inferior OS (mean, 1.7 years vs 2.9 years; P = .012). In a multivariate Cox proportional hazards model, high-risk disease (hazard ratio [HR], 2.34; 95% Cl, 1.09-5.28; P = .029) and pretransplantation c-peptide level >3.6 ng/mL (HR, 1.05; 95% Cl, 1.01-1.09; P = .013) were independent predictors of OS when adjusted for systemic steroids and regimen intensity. We suspect that diabetes mellitus in the immediate posttransplantation period may be mediated via an inflammatory pathway that contributes to insulin resistance in the host adipose tissue. Our study is the first to report the risk factors of early PTDM in patients undergoing allo-SCT and identifies pretransplantation c-peptide as an independent predictor of diabetes and survival. Biol Blood Marrow Transplant 17: 86-92 (2011) (C) 2011 American Society for Blood and Marrow Transplantation

引用

页码：86 / 92

页数：7

共 20 条

[1] Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens [J].

Abou-Mourad, Y. R. ;

Lau, B. C. ;

Barnett, M. J. ;

Forrest, D. L. ;

Hogge, D. E. ;

Nantel, S. H. ;

Nevill, T. J. ;

Shepherd, J. D. ;

Smith, C. A. ;

Song, K. W. ;

Sutherland, H. J. ;

Toze, C. L. ;

Lavoie, J. C. .

BONE MARROW TRANSPLANTATION, 2010, 45 (02) :295-302

[2] Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation [J].

Annaloro, C. ;

Usardi, P. ;

Airaghi, L. ;

Giunta, V. ;

Forti, S. ;

Orsatti, A. ;

Baldini, M. ;

Delle Volpe, A. ;

Deliliers, G. Lambertenghi .

BONE MARROW TRANSPLANTATION, 2008, 41 (09) :797-804

[3] Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study [J].

Baker, K. Scott ;

Ness, Kirsten K. ;

Steinberger, Julia ;

Carter, Andrea ;

Francisco, Liton ;

Burns, Linda J. ;

Sklar, Charles ;

Forman, Stephen ;

Weisdorf, Daniel ;

Gurney, James G. ;

Bhatia, Smita .

BLOOD, 2007, 109 (04) :1765-1772

[4] Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study [J].

Baker, KS ;

Gurney, JG ;

Ness, KK ;

Bhatia, R ;

Forman, SJ ;

Francisco, L ;

McGlave, PB ;

Robison, LL ;

Snyder, DS ;

Weisdorf, DJ ;

Bhatia, S .

BLOOD, 2004, 104 (06) :1898-1906

[5] New-onset diabetes after transplantation: 2003 International Consensus Guidelines [J].

Davidson, J ;

Wilkinson, A ;

Dantal, J ;

Dotta, F ;

Haller, H ;

Hernández, D ;

Kasiske, BL ;

Kiberd, B ;

Krentz, A ;

Legendre, C ;

Marchetti, P ;

Markell, M ;

van der Woude, FJ ;

Wheeler, DC .

TRANSPLANTATION, 2003, 75 (10) :SS3-SS24

[6]

ENGELHARDT BG, 2010, BONE MARROW IN PRESS

[7] Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters [J].

Feuerer, Markus ;

Herrero, Laura ;

Cipolletta, Daniela ;

Naaz, Afia ;

Wong, Jamie ;

Nayer, Ali ;

Lee, Jongsoon ;

Goldfine, Allison B. ;

Benoist, Christophe ;

Shoelson, Steven ;

Mathis, Diane .

NATURE MEDICINE, 2009, 15 (08) :930-U137

[8] The homeostasis model in the San Antonio Heart Study [J].

Haffner, SM ;

Miettinen, H ;

Stern, MP .

DIABETES CARE, 1997, 20 (07) :1087-1092

[9] The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients [J].

Hammer, Marilyn J. ;

Casper, Corey ;

Gooley, Ted A. ;

O'Donnell, Paul V. ;

Boeckh, Michael ;

Hirsch, Irl B. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (03) :344-351

[10] High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation [J].

Majhail, N. S. ;

Flowers, M. E. ;

Ness, K. K. ;

Jagasia, M. ;

Carpenter, P. A. ;

Arora, M. ;

Arai, S. ;

Johnston, L. ;

Martin, P. J. ;

Baker, K. S. ;

Lee, S. J. ;

Burns, L. J. .

BONE MARROW TRANSPLANTATION, 2009, 43 (01) :49-54

← 1 2 →